跳至主要内容
临床试验/NCT02393963
NCT02393963已完成2 期

Role of Low Dose Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty: A Randomized Placebo Controlled Study

Orthopaedic Innovation Centre1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2015年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
140
试验地点
1
主要终点
Change from Baseline in hemoglobin during hospital stay

研究概览

简要总结

This is a randomized, double blinded, controlled trial in patients undergoing elective Total Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA). The study group will receive intra-articular Tranexamic Acid (TXA) while the control group will receive normal saline placebo.

详细描述

The primary purpose of this study is to determine if intra-articular administration of low dose TXA following THA and TKA results in a clinically relevant reduction in blood loss. The secondary purpose is to determine if there is an increased risk of thromboembolic phenomena with the use of TXA following elective THA and TKA. The primary outcome metric will be - drop in hemoglobin following surgery; secondary metrics include blood loss, transfusion rate, d-dimers, troponin levels, symptomatic deep venous thrombosis (DVT) and pulmonary embolism (PE), vascular events (myocardial infarction, stroke), major and minor bleeding, and death.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • with osteoarthritis
  • scheduled for elective primary unilateral THR or TKR
  • provided informed consent
  • can read, write and speak English

排除标准

  • history of arterial or venous thromboembolic disease (myocardial infarction, symptomatic ischemic heart disease, atrial fibrillation, cerebrovascular accident, deep-vein thrombosis, pulmonary embolus, or thrombogenic cardiac valvular disease or rhythm disease)
  • pre-operative Hg of <120 g/L
  • Known allergy to Tranexamic Acid
  • Coagulation disorder
  • Acquired disturbances of color vision
  • Hepatic insufficiency, any history of liver disease
  • Renal insufficiency (on dialysis)
  • Preoperative prophylactic use of antiplatelet or anticoagulant therapy such as Clopidogrel, Warfarin, dabigatran or Rivaroxaban. This does not include low dose Aspirin (81mg)
  • Patients with a history of subarachnoid hemorrhage [20]
  • Simultaneous bilateral THA or TKA
  • Any contra-indication for spinal anesthesia
  • Allergy to Celecoxib, which will be the only nonsteroidal anti-inflammatory drugs (NSAID) used in the multi-modal analgesia regime.
  • Retinal vein or retinal artery occlusion
  • Female on oral contraceptive pills and/or premenopausal
  • Concurrently taking hydrochlorothiazide, desmopressin, sulbactam-ampicillin, carbazochrome, ranitidine and/or nitroglycerin for the duration of the surgery.

研究组 & 干预措施

Tranexamic Acid

Experimental

Intra-articular administration of low dose Tranexamic acid

干预措施: Tranexamic Acid (Drug)

Placebo

Placebo Comparator

Sodium Chloride

干预措施: Placebo (Other)

结局指标

主要结局

Change from Baseline in hemoglobin during hospital stay

时间窗: routinely measured post-op day 1 and 3

次要结局

  • Serum Troponin(Every 6 hours for 24 hours post-op)
  • D-dimer(Post-op day 1 and 2)

研究者

发起方
Orthopaedic Innovation Centre
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验